These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 7713987)

  • 1. "Atypical" multidrug resistance in human ovarian cancer cell line A2780 selected for resistance to doxorubicin (A2780 DX3).
    Cimoli G; Valenti M; Noviello E; Parodi S; Mazzoni A; Rovini E; De Sessa F; Russo P
    J Cancer Res Clin Oncol; 1995; 121(3):155-63. PubMed ID: 7713987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversal of "atypical"-multidrug resistance by recombinant human tumor necrosis factor in the human ovarian cancer cell line A2780-DX3.
    Cimoli G; Valenti M; Parodi S; Mazzoni A; De Sessa F; Conte P; Russo P
    Oncol Res; 1993; 5(8):311-23. PubMed ID: 8012063
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sister-chromatid exchanges, chromosomal aberrations and cytotoxicity produced by topoisomerase II-targeted drugs in sensitive (A2780) and resistant (A2780-DX3) human ovarian cancer cells: correlations with the formation of DNA double-strand breaks.
    Noviello E; Aluigi MG; Cimoli G; Rovini E; Mazzoni A; Parodi S; De Sessa F; Russo P
    Mutat Res; 1994 Nov; 311(1):21-9. PubMed ID: 7526171
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circumvention of atypical multidrug resistance with tumor necrosis factor.
    Cimoli G; Valenti M; Parodi S; De Sessa F; Russo P
    Jpn J Cancer Res; 1994 Feb; 85(2):135-8. PubMed ID: 8144394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism of resistance to cisplatin in a human ovarian-carcinoma cell line selected for resistance to doxorubicin: possible role of p53.
    Vikhanskaya F; Clerico L; Valenti M; Stanzione MS; Broggini M; Parodi S; Russo P
    Int J Cancer; 1997 Jul; 72(1):155-9. PubMed ID: 9212237
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cellular determinants of resistance to indolocarbazole analogue 6-N-formylamino-12,13-dihydro-1,11-dihydroxy-13(beta-D-glucopyranosyl)- 5H-indolo[2,3-alpha]pyrrolo[3,4-c]carbazole-5,7(6H)-dione (NB-506), a novel potent topoisomerase I inhibitor, in multidrug-resistant human tumor cells.
    Vanhoefer U; Voigt W; Hilger RA; Yin MB; Harstrick A; Seeber S; Rustum YM
    Oncol Res; 1997; 9(9):485-94. PubMed ID: 9495454
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationship between cytotoxicity, drug accumulation, DNA damage and repair of human ovarian cancer cells treated with doxorubicin: modulation by the tiapamil analog RO11-2933.
    Alaoui Jamali MA; Yin MB; Mazzoni A; Bankusli I; Rustum YM
    Cancer Chemother Pharmacol; 1989; 25(2):77-83. PubMed ID: 2598402
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Human splicing factor SPF45 (RBM17) confers broad multidrug resistance to anticancer drugs when overexpressed--a phenotype partially reversed by selective estrogen receptor modulators.
    Perry WL; Shepard RL; Sampath J; Yaden B; Chin WW; Iversen PW; Jin S; Lesoon A; O'Brien KA; Peek VL; Rolfe M; Shyjan A; Tighe M; Williamson M; Krishnan V; Moore RE; Dantzig AH
    Cancer Res; 2005 Aug; 65(15):6593-600. PubMed ID: 16061639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estrogen-induced potentiation of DNA damage and cytotoxicity in human breast cancer cells treated with topoisomerase II-interactive antitumor drugs.
    Epstein RJ; Smith PJ
    Cancer Res; 1988 Jan; 48(2):297-303. PubMed ID: 2825970
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA strand breaks produced by etoposide (VP-16,213) in sensitive and resistant human breast tumor cells: implications for the mechanism of action.
    Sinha BK; Haim N; Dusre L; Kerrigan D; Pommier Y
    Cancer Res; 1988 Sep; 48(18):5096-100. PubMed ID: 2842045
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mitoxantrone resistance in HL-60 leukemia cells: reduced nuclear topoisomerase II catalytic activity and drug-induced DNA cleavage in association with reduced expression of the topoisomerase II beta isoform.
    Harker WG; Slade DL; Drake FH; Parr RL
    Biochemistry; 1991 Oct; 30(41):9953-61. PubMed ID: 1655025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA breakage in human lung carcinoma cells and nuclei that are naturally sensitive or resistant to etoposide and teniposide.
    Long BH; Musial ST; Brattain MG
    Cancer Res; 1986 Aug; 46(8):3809-16. PubMed ID: 3015377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduction in drug-induced DNA double-strand breaks associated with beta1 integrin-mediated adhesion correlates with drug resistance in U937 cells.
    Hazlehurst LA; Valkov N; Wisner L; Storey JA; Boulware D; Sullivan DM; Dalton WS
    Blood; 2001 Sep; 98(6):1897-903. PubMed ID: 11535527
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mitoxantrone-DNA binding and the induction of topoisomerase II associated DNA damage in multi-drug resistant small cell lung cancer cells.
    Smith PJ; Morgan SA; Fox ME; Watson JV
    Biochem Pharmacol; 1990 Nov; 40(9):2069-78. PubMed ID: 2173600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential stabilization of topoisomerase-II-DNA cleavable complexes by doxorubicin and etoposide in doxorubicin-resistant rat glioblastoma cells.
    Montaudon D; Pourquier P; Denois F; de Tinguy-Moreaud E; Lagarde P; Robert J
    Eur J Biochem; 1997 Apr; 245(2):307-15. PubMed ID: 9151958
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Etoposide-induced DNA damage in human tumor cells: requirement for cellular activating factors.
    Sinha BK; Eliot HM
    Biochim Biophys Acta; 1991 Sep; 1097(2):111-6. PubMed ID: 1655044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytoplasmic membrane cholesterol and doxorubicin cytotoxicity in drug-sensitive and multidrug-resistant human ovarian cancer cells.
    Mazzoni A; Trave F
    Oncol Res; 1993; 5(2):75-82. PubMed ID: 8364256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HT1080/DR4: a P-glycoprotein-negative human fibrosarcoma cell line exhibiting resistance to topoisomerase II-reactive drugs despite the presence of a drug-sensitive topoisomerase II.
    Zwelling LA; Slovak ML; Doroshow JH; Hinds M; Chan D; Parker E; Mayes J; Sie KL; Meltzer PS; Trent JM
    J Natl Cancer Inst; 1990 Oct; 82(19):1553-61. PubMed ID: 1976136
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dipyridamole reverses the resistance to topoisomerase II inhibitors but not to antimicrotubule agents in multidrug-resistant melanoma cells.
    Damle B; Desai P
    Oncol Res; 1994; 6(2):49-57. PubMed ID: 7949465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance.
    Schneider E; Horton JK; Yang CH; Nakagawa M; Cowan KH
    Cancer Res; 1994 Jan; 54(1):152-8. PubMed ID: 7903202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.